Johnson Pharma

Which are the latest news on Johnson Pharma?

Why is Johnson Pharmacare Ltd falling/rising?

As of 23-Jun, Johnson Pharmacare Ltd's stock price is at 0.50, reflecting a decline of 1.96% and significant drops over various periods, including a 41.86% decrease over the past year. The stock is trading below all moving averages, indicating a bearish trend, and investor interest has waned, with delivery volume down by 21.59%.

As of 23-Jun, Johnson Pharmacare Ltd's stock price is falling, currently at 0.50, which reflects a change of -0.01 or -1.96%. This decline is evident in the stock's performance over various periods, showing a 1-week drop of 1.96%, a 1-month decrease of 9.09%, and a year-to-date decline of 13.79%. Over the past year, the stock has fallen significantly by 41.86%, while the benchmark Sensex has only decreased by 6.96% during the same period.<BR><BR>Additionally, the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume dropping by 21.59% compared to the 5-day average, suggesting reduced interest from investors. Despite outperforming its sector by 0.9% today, these factors contribute to the overall downward movement of Johnson Pharmacare Ltd's stock price.

How big is Johnson Pharma?

As of 10th June, Johnson Pharmacare Ltd has a market capitalization of 29.00 Cr, classifying it as a Micro Cap company, with reported Net Sales of 0.00 Cr and a Net Profit loss of 55.72 Cr over the latest 4 quarters. The balance sheet for March 2025 shows Shareholder's Funds of 56.17 Cr and Total Assets of 57.93 Cr.

As of 10th June, Johnson Pharmacare Ltd has a market capitalization of 29.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 0.00 Cr and a Net Profit loss of 55.72 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 56.17 Cr and Total Assets of 57.93 Cr.

Who are in the management team of Johnson Pharma?

The management team of Johnson Pharma includes Ramanlal Trivedi (Whole Time Director & CFO), Pareshbhai Sengal (Independent Director), and Manisha Maneklal Patel (Independent Director), who are responsible for the company's strategic direction and governance.

The management team of Johnson Pharma includes the following individuals:<BR><BR>1. **Ramanlal Trivedi** - Whole Time Director & CFO<BR>2. **Pareshbhai Sengal** - Independent Director<BR>3. **Manisha Maneklal Patel** - Independent Director<BR><BR>These members play key roles in guiding the company's strategic direction and governance.

Who are the peers of the Johnson Pharma?

Johnson Pharma's peers include Evans Electric, Shreevatsaa Fin., S P Capital Fin., and others. In terms of management risk, Johnson Pharma is rated below average, with a 1-year return of -43.33%, better than Evans Electric but worse than Shreevatsaa Fin. at 43.40%.

Peers: The peers of Johnson Pharma are Evans Electric, Shreevatsaa Fin., S P Capital Fin., Innovative Ideal, Monotype India, Esaar (India), Kaarya Facilit., ERP Soft Systems, and Happy Square.<BR><BR>Quality Snapshot: Excellent management risk is observed at S P Capital Fin. and Esaar (India), while Average management risk is found at Evans Electric. Below Average management risk is noted for Johnson Pharma, Innovative Ideal, Kaarya Facilit., and ERP Soft Systems. Growth is classified as Good for S P Capital Fin. and Esaar (India), Average for Johnson Pharma, and Below Average for Evans Electric, Innovative Ideal, Shreevatsaa Fin., Kaarya Facilit., and ERP Soft Systems. Capital Structure is Excellent at S P Capital Fin. and Esaar (India), Good at Johnson Pharma and ERP Soft Systems, and Below Average at Innovative Ideal and Kaarya Facilit. The rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shreevatsaa Fin. at 43.40%, while the lowest is Evans Electric at -66.30%. Johnson Pharma's 1-year return of -43.33% is better than Evans Electric but worse than Shreevatsaa Fin. Additionally, the six-month return is negative for Evans Electric, Innovative Ideal, Kaarya Facilit., ERP Soft Systems, and Monotype India.

What does Johnson Pharma do?

Johnson Pharmacare Ltd is a micro-cap pharmaceutical company, originally founded in 1994, that reported a net profit of -56 Cr for March 2026 and has a market cap of INR 29 Cr. The company has undergone several name changes, with its latest rebranding occurring in August 2021.

Overview:<BR>Johnson Pharmacare Ltd is a pharmaceutical company operating in the diversified commercial services industry and classified as a micro-cap entity.<BR><BR>History:<BR>The company was originally incorporated in 1994 under the name 'Robinson Worldwide Trade Limited.' It underwent a name change to 'Sun & Shine Worldwide Limited' in September 2011 and was rebranded to 'Johnson Pharmacare Limited' effective August 23, 2021. The latest quarterly results reported are for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -56 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 29 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 21<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 21.32<BR>Return on Equity: -4,146.00%<BR>Price-to-Book: 28.60<BR><BR>Contact Details:<BR>Address: Office No 302 Munisuvrat Navg, NTC B-68 Swastik Society CG Rd Ahmedabad Gujarat : 380009<BR>Email: sunandshineworldwideltd@gmail.com<BR>Website: http://www.sunandshineworldwidetradelimited.quest

Should I buy, sell or hold Johnson Pharmacare Ltd?

When is the next results date for Johnson Pharmacare Ltd?

The next results date for Johnson Pharmacare Ltd is 14 February 2026.

The next results date for Johnson Pharmacare Ltd is scheduled for 14 February 2026.

How has been the historical performance of Johnson Pharma?

Johnson Pharma has experienced significant declines in revenue and profitability, with net sales dropping from 3.26 Cr in March 2022 to 0.00 Cr by March 2025, resulting in increasing operating and net losses. Total assets and liabilities decreased, and cash flow turned negative, indicating a downward trend in financial stability.

Answer:<BR>The historical performance of Johnson Pharma shows significant fluctuations in revenue and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Johnson Pharma's net sales peaked at 3.26 Cr in March 2022 but have since dropped to 0.00 Cr in March 2025. Total operating income followed a similar trend, decreasing from 3.26 Cr in March 2022 to 0.00 Cr in March 2025. The company experienced an operating profit of 0.13 Cr in March 2022, but this turned negative, resulting in an operating loss of 0.41 Cr by March 2025. Profit before tax also saw a decline, moving from a profit of 0.13 Cr in March 2022 to a loss of 0.58 Cr in March 2025. The profit after tax mirrored this trend, with losses increasing from 0.10 Cr in March 2022 to 0.58 Cr in March 2025. Total assets decreased from 59.98 Cr in March 2022 to 57.93 Cr in March 2025, while total liabilities also fell from 59.98 Cr to 57.93 Cr in the same period. Cash flow from operating activities turned negative, with a cash outflow of 1.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2022. Overall, the financial data indicates a downward trajectory in both operational performance and financial stability for Johnson Pharma.

Is Johnson Pharma overvalued or undervalued?

As of May 27, 2024, Johnson Pharma is considered overvalued with a PE ratio of -48.95 and has seen a year-to-date decline of 21.05%, indicating a challenging market position compared to its peers.

As of 27 May 2024, Johnson Pharma's valuation grade has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently assessed as overvalued, with a PE ratio of -48.95, an EV to EBIT of -50.90, and an EV to Capital Employed of 0.87. These ratios suggest that the company's earnings and operational efficiency are under considerable strain, leading to negative valuations.<BR><BR>In comparison to its peers, Johnson Pharma's valuation metrics are starkly unfavorable. For instance, MMTC, categorized as risky, has a PE ratio of 119.39, while Optiemus Infra, deemed fair, boasts a PE of 82.35. The stark contrast in these ratios highlights Johnson Pharma's challenging position within the diversified commercial services sector. Furthermore, the company's recent stock performance shows a year-to-date decline of 21.05%, in contrast to the Sensex's 5.58% gain, reinforcing the notion that Johnson Pharma is struggling relative to broader market trends.

What is the technical trend for Johnson Pharma?

As of April 30, 2025, Johnson Pharma's technical trend has shifted to a moderate bearish stance, supported by bearish indicators across MACD, RSI, and Bollinger Bands on both weekly and monthly charts, despite a mildly bullish KST on the weekly.

As of 30 April 2025, the technical trend for Johnson Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart and a bearish RSI on the monthly chart. Both Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The daily moving averages confirm a bearish outlook. Although the KST shows mildly bullish on the weekly, it is mildly bearish on the monthly, indicating a lack of strong upward momentum. Overall, the bearish sentiment is reinforced by the Dow Theory, which shows a mildly bearish trend on the weekly and no trend on the monthly.

Who are the top shareholders of the Johnson Pharma?

The top shareholders of Johnson Pharma are primarily individual investors, holding 85.56% of the shares, with Jagkarta Agencies Private Limited as the largest public shareholder at 2.78%. There are no institutional holdings or pledged promoter holdings reported.

The top shareholders of Johnson Pharma primarily consist of individual investors, who hold a significant 85.56% of the shares. The highest public shareholder is Jagkarta Agencies Private Limited, with a holding of 2.78%. There are no institutional holdings or pledged promoter holdings reported, and no mutual funds or foreign institutional investors are involved.

What is the bonus history of the Johnson Pharma?

Johnson Pharma announced a 1:10 bonus issue on April 7, 2022, with a record date of April 8, 2022, meaning shareholders received one additional share for every ten shares held.

Johnson Pharma has a recent bonus history that includes a 1:10 bonus issue announced on April 7, 2022. The record date for this bonus was April 8, 2022. This means that for every 10 shares held, shareholders received an additional share as part of the bonus issue. If you have any more questions about the company or its financials, feel free to ask!

Has Johnson Pharma declared dividend?

No Dividend History Available